Abortion. Is RU 486/PG in its current form likely to be appropriate for women in Bangladesh?
Kabir
S
S
Germain
A
A
D000019:Abortifacient Agents; D000028:Abortion, Induced; D001208:Asia; D001459:Bangladesh; D001695:Biology; D002986:Clinical Trials as Topic; D003267:Contraception; D003268:Contraception Behavior; D003281:Contraceptives, Postcoital; D003906:Developing Countries; D004703:Endocrine System; D005069:Evaluation Studies as Topic; D005193:Family Planning Services; D005333:Fetus; D005865:Gestational Age; D006302:Health Services Research; D006727:Hormone Antagonists; D006728:Hormones; D008598:Menstruation; D015735:Mifepristone; D009934:Organization and Administration; D010342:Patient Acceptance of Health Care; D010827:Physiology; D011057:Politics; D011247:Pregnancy; D015397:Program Evaluation; D011453:Prostaglandins; D011465:Prostaglandins, Synthetic; D011639:Public Opinion; D011787:Quality of Health Care; D012098:Reproduction; D012106:Research; D014930:Women
D000019:Abortifacient Agents; D003281:Contraceptives, Postcoital; D006727:Hormone Antagonists; D006728:Hormones; D011453:Prostaglandins; D011465:Prostaglandins, Synthetic; D015735:Mifepristone
Abortifacient Agents--beneficial effects; Abortifacient Agents--cost; Abortifacient Agents--side effects; Abortion, Drug Induced; Abortion, Induced; Asia; Bangladesh; Biology; Clinical Research; Clinical Trials; Contraception; Contraceptive Usage; Critique; Developing Countries; Endocrine System; Family Planning; Fertility Control, Postcoital; Fertility Control, Postconception; Fetus; Gestational Age; Health Services Evaluation; Hormone Antagonists; Hormones; Interest Groups; Menstrual Regulation; Method Acceptability; Organization And Administration; Physiology; Political Factors; Pregnancy; Pro-choice Groups; Program Evaluation; Programs; Prostaglandins; Prostaglandins, Synthetic; Quality Of Health Care; Reproduction; Research Methodology; Ru-486; Southern Asia; Women's Groups